Ragweed Pollen Allergy - Pipeline Review, H1 2017

Ragweed Pollen Allergy - Pipeline Review, H1 2017

Mar 2009 Global Markets Direct Pharmaceutical26 Pages Price :
$ 2000
Ragweed Pollen Allergy - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ragweed Pollen Allergy Pipeline Review, H1 2017, provides an overview of the Ragweed Pollen Allergy (Immunology) pipeline landscape.

Ragweed allergy occurs when ragweed pollen in the air enters the nose and throat of people who are allergic to that pollen, it can cause allergy and asthma symptoms. Symptoms include sneezing, runny or stuffy nose, itchy throat or inside of ears, hives, and swollen eyelids and itchy eyes. Treatment includes decongestant, antihistamine and nasal corticosteroid.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ragweed Pollen Allergy Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Ragweed Pollen Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ragweed Pollen Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Ragweed Pollen Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Unknown stages are 4 and 1 respectively.

Ragweed Pollen Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ragweed Pollen Allergy (Immunology).
- The pipeline guide reviews pipeline therapeutics for Ragweed Pollen Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ragweed Pollen Allergy (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ragweed Pollen Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ragweed Pollen Allergy (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ragweed Pollen Allergy (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ragweed Pollen Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Ragweed Pollen Allergy - Overview
Ragweed Pollen Allergy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Ragweed Pollen Allergy - Therapeutics Assessment
Assessment by Route of Administration
Assessment by Molecule Type
Ragweed Pollen Allergy - Companies Involved in Therapeutics Development
Anergis SA
ASIT Biotech SA
Astellas Pharma Inc
Biomay AG
Ragweed Pollen Allergy - Drug Profiles
AllerR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BM-34 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Multi-LAMP-Vax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rag-ASIT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ragweed Pollen Allergy - Dormant Projects
Ragweed Pollen Allergy - Discontinued Products
Ragweed Pollen Allergy - Product Development Milestones
Featured News & Press Releases
Dec 19, 2014: Anergis Granted U.S. Patent for Ragweed Allergy Vaccine AllerR
Feb 21, 2013: Anergis To Present Preclinical Data On Ragweed Allergy Vaccine Candidate AllerR At AAAAI 2013 Annual Meeting
Jun 14, 2012: Anergis Reaches Several Preclinical Development Milestones With Ragweed Pollen Vaccine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Ragweed Pollen Allergy, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Ragweed Pollen Allergy - Pipeline by Anergis SA, H1 2017
Ragweed Pollen Allergy - Pipeline by ASIT Biotech SA, H1 2017
Ragweed Pollen Allergy - Pipeline by Astellas Pharma Inc, H1 2017
Ragweed Pollen Allergy - Pipeline by Biomay AG, H1 2017
Ragweed Pollen Allergy - Dormant Projects, H1 2017
Ragweed Pollen Allergy - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Ragweed Pollen Allergy, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ 2000
$ 4000

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top